What is claimed:

1. An oral suspension comprising Drotaverine or a salt thereof, preferably Drotaverine hydrochloride, wherein the Drotaverine or salt thereof is in a concentration of greater than 4 mg/mL, preferably 5-30 mg/mL.

2. The oral suspension of claim 1, wherein the liquid oral dosage form comprises a Drotaverine-resin complex, wherein the ratio of Drotaverine to resin is 1:2 to 1:6, preferably wherein the Drotaverine-resin complex comprises granules, wherein the size of the granules are in the range of 300 microns to 150 microns; and preferably wherein the resin is selected from Kyron 114, Kyron 314, Indion 204, Indion 234, Indion 294, or a combination thereof, more preferably wherein the resin comprises Kyron 114.

3. The oral suspension of claim 1 or 2, wherein the dosage form further comprises an anti-flatulent agent, preferably wherein the anti-flatulent agent is simethicone or activated dimethicone, more preferably wherein the dosage form comprises 10-80 mg/mL simethicone or activated dimethicone.

4. The oral suspension of any one of claims 1-3, wherein the dosage form comprises a water-soluble polymer, preferably wherein the water-soluble polymer comprises a hydroxypropyl methylcellulose, a polyvinylpyrrolidone, gelatin, a soluble starch, or a combination thereof.

5. The oral suspension of any one of claims 1-4, wherein the suspension comprises a solvent, wherein the solvent comprises a sugar alcohol, a polyhydric alcohol, or a combination thereof, preferably wherein the solvent comprises a sugar alcohol and the sugar alcohol is sorbitol, or sorbitol (70% liquid) and/or wherein the solvent comprises a polyhydric alcohol and the polyhydric alcohol is glycerin.

6. The oral suspension of claim 5 wherein the solvent comprises sorbitol (70% liquid) and a glycerin in a ratio of 1:1 to 9:1, preferably wherein the ratio of sorbitol (70% liquid) to glycerin is 2:1 to 8:1.

7. The oral suspension of any one of claims 1-6, wherein the suspension comprises a suspending agent, wherein the suspending agent comprises sodium carboxymethylcellulose (Sod CMC), xanthan gum, or a combination thereof, preferably wherein the suspending agent is in an amount of 0.05% to 3.0% w/w, more preferably wherein the suspending agent is in an amount of 0.08% to 2.0% w/w.

8. The oral suspension of any one of claims 1-7, wherein the dosage form comprises a sweetener, preferably wherein the sweetener is an artificial sweetener comprising aspartame, sodium saccharin, acesulfame K, sucralose, or a combination thereof, or wherein the sweetener is a natural sweetener comprising sucrose, sorbitol, or a combination thereof.

9. The oral suspension of any one of claims 1-8, wherein the dosage form comprises a flavouring agent, a colorant, an antioxidant, a chelating agent, a surfactant, a wetting agent, a pH modifier, an acidifier, a preservative, a solvent, or a combination thereof, preferably wherein the antioxidant is in an amount of 0.05% to 4% w/w, more preferably wherein the antioxidant is in an amount of 0.1% to 3.0% w/w .

10. The oral suspension of any one of claims 1-9, wherein the dosage form exhibits dosage uniformity, uniform dispersibility, and re-dispersibility as measured by High-Performance Liquid Chromatography.

11. An oral suspension comprising Drotaverine hydrochloride, Kyron114, Simethicone, Xanthan gum, Povidone (Kollidon 12 PF), Sucrose, Citric acid, Tween-80, Sodium metabisulphite, Sorbitol 70%, glycerin, Methyl Paraben, Propyl Paraben, and a flavouring agent, wherein the Drotaverine hydrochloride and Kyron 114 comprise a drug-resin complex, and wherein the Drotaverine hydrochloride and Kyron 114 are in a 1:3 ratio.

12. The oral suspension of any one of claims 1-11, wherein the suspension is stable for three months when stored at 40° C and 75% RH as accelerated storage conditions, preferably for six months when stored at 40° C and 75% RH as accelerated storage conditions.

13. The oral suspension of any one of claims 1-12, wherein the suspension is stable for three months when stored at 25-30° C and 60-75% RH as long-term storage conditions, preferably wherein the suspension is stable for six months when stored at 25-30° and 60-75% RH C as long-term storage conditions, more preferably wherein said suspension is stable for 2 years when stored at 25-30° C and 60-75% RH as long-term storage conditions.

14. The oral suspension of any one of claims 1-13, wherein the liquid oral dosage form exhibits improved taste or improved aftertaste or improved palatability.

15. A method of preparing an oral suspension of Drotaverine or salt thereof comprising:

a. heating a quantity of water and adding at least one preservative and milled sucrose, stirring the resulting mixture continuously until dissolved to obtain a solution;

b. cooling the solution to obtain a cooled solution;

c. adding at least one acidifier and at least one antioxidant into the cooled solution until dissolved to obtain a solution;

d. adding at least one wetting agent into the solution until dissolved to obtain a solution;

e. adding at least one stabilizer and a dispersion that has been obtained by soaking at least one suspending agent in water, until dissolved to obtain a bulk solution;

f. sifting a drug-resin complex comprising Drotaverine or a salt thereof through a sieve, preferably wherein the sieve is a mesh no larger than

300 microns, adding the bulk solution obtained in step (e), and stirring until dissolved to obtain a bulk suspension; and

g. adding a quantity of water to the bulk suspension to obtain a suspension of Drotaverine or a salt thereof.

16. The method of claim 15, wherein the method comprises adding simethicone or activated dimethicone with Drotaverine in step (f).

17. The method of claim 15 or 16, wherein the drug-resin complex comprises Kyron 114, Kyron 314, Indion 204, Indion 234, or Indion 294, or a combination thereof and/or wherein the drug-resin complex comprising Drotaverine or a salt thereof are mixed in a ratio of 1:2 to 1:6.

18. The method of any one of claims 15-17, wherein the drug-resin complex is air dried or dried using drying equipment, and/or wherein the dried drug-resin complex has less than 5.0% w/w of water.

19. Use of an oral suspension comprising Drotaverine or a salt thereof and Simethicone, according to any one of claims 1-14, in the manufacture of a medicament for treating abdominal pain in a subject.